Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 5
1984 4
1985 3
1986 5
1987 10
1988 7
1989 3
1990 9
1991 9
1992 4
1993 7
1994 7
1995 8
1996 17
1997 8
1998 20
1999 8
2000 11
2001 12
2002 20
2003 16
2004 13
2005 16
2006 11
2007 12
2008 13
2009 11
2010 12
2011 19
2012 14
2013 13
2014 13
2015 11
2016 12
2017 9
2018 17
2019 16
2020 17
2021 14
2022 6
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

419 results

Results by year

Filters applied: . Clear all
Page 1
End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.
Kato K, Izutsu K, Nishikori M, Shibayama H, Maeda Y, Yoshimura K, Tateishi U, Miyamoto T, Matsuda Y, Ishikawa J, Rai S, Takahashi T, Yamauchi T, Matsumura I, Akashi K, Kanakura Y, Suzumiya J. Kato K, et al. Among authors: kanakura y. Int J Hematol. 2024 Mar 22. doi: 10.1007/s12185-024-03738-8. Online ahead of print. Int J Hematol. 2024. PMID: 38519820
Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor BCR-ABL (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Hidaka M, Inokuchi K, Uoshima N, Takahashi N, Yoshida N, Ota S, Nakamae H, Iwasaki H, Watanabe K, Kosaka Y, Komatsu N, Meguro K, Najima Y, Eto T, Kondo T, Kimura S, Yoshida C, Ishikawa Y, Sawa M, Hata T, Horibe K, Iida H, Shimomura T, Dobashi N, Sugiura I, Makiyama J, Miyagawa N, Sato A, Ito R, Matsumura I, Kanakura Y, Naoe T. Hidaka M, et al. Among authors: kanakura y. Jpn J Clin Oncol. 2024 Feb 7;54(2):153-159. doi: 10.1093/jjco/hyad156. Jpn J Clin Oncol. 2024. PMID: 37986553 Free PMC article.
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum.
Shimura Y, Shibayama H, Nakaya A, Yamamura R, Imada K, Kaneko H, Hanamoto H, Fuchida SI, Tanaka H, Kosugi S, Kiyota M, Matsui T, Kanda J, Iida M, Matsuda M, Uoshima N, Shibano M, Karasuno T, Hamada T, Ohta K, Ito T, Yagi H, Yoshihara S, Shimazaki C, Nomura S, Hino M, Takaori-Kondo A, Matsumura I, Kanakura Y, Kuroda J. Shimura Y, et al. Among authors: kanakura y. Int J Hematol. 2023 Nov;118(5):609-617. doi: 10.1007/s12185-023-03653-4. Epub 2023 Sep 5. Int J Hematol. 2023. PMID: 37668833
A longitudinal analysis of paroxysmal nocturnal haemoglobinuria-type cells in patients with bone marrow failure: Results of a prospective multi-centre study in Japan.
Ishiyama K, Yonemura Y, Kawaguchi T, Hosokawa K, Sugimori C, Ueda Y, Takamori H, Obara N, Noji H, Shirasugi Y, Ando K, Shichishima T, Ninomiya H, Chiba S, Nishimura JI, Kanakura Y, Nakao S. Ishiyama K, et al. Among authors: kanakura y. Br J Haematol. 2023 Nov;203(3):468-476. doi: 10.1111/bjh.19048. Epub 2023 Aug 31. Br J Haematol. 2023. PMID: 37654088
Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Munakata W, Izutsu K, Mishima Y, Nagai H, Ishihara Y, Suzumiya J, Kanakura Y, Nanki T, Miyake T, Kawasaki A, Yoshinaga T, Ishizawa K. Munakata W, et al. Among authors: kanakura y. Jpn J Clin Oncol. 2023 Oct 4;53(10):912-921. doi: 10.1093/jjco/hyad082. Jpn J Clin Oncol. 2023. PMID: 37486002 Free PMC article. Clinical Trial.
Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors.
Nishimura JI, Soubret A, Arase N, Buatois S, Hotta M, Charoin JE, Ito Y, Sreckovic S, Takamori H, Bucher C, Ueda Y, Hernández-Sánchez J, Gotanda K, Jordan G, Shinomiya K, Ramos J, Kim JS, Panse J, de Latour RP, Röth A, Morii E, Schrezenmeier H, Isaka Y, Sica S, Kanakura Y, Yoon SS, Kinoshita T, Paz-Priel I, Sostelly A. Nishimura JI, et al. Among authors: kanakura y. Clin Pharmacol Ther. 2023 Apr;113(4):904-915. doi: 10.1002/cpt.2851. Epub 2023 Feb 12. Clin Pharmacol Ther. 2023. PMID: 36660902
Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum.
Nakaya A, Shibayama H, Nakatani E, Shimura Y, Kosugi S, Tanaka H, Fuchida SI, Kanda J, Uoshima N, Kaneko H, Imada K, Ohta K, Ito T, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Nakaya A, et al. Among authors: kanakura y. EJHaem. 2021 Oct 20;2(4):765-773. doi: 10.1002/jha2.284. eCollection 2021 Nov. EJHaem. 2021. PMID: 35845216 Free PMC article.
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.
Morita Y, Nannya Y, Ichikawa M, Hanamoto H, Shibayama H, Maeda Y, Hata T, Miyamoto T, Kawabata H, Takeuchi K, Tanaka H, Kishimoto J, Miyano S, Matsumura I, Ogawa S, Akashi K, Kanakura Y, Mitani K. Morita Y, et al. Among authors: kanakura y. Int J Hematol. 2022 Nov;116(5):659-668. doi: 10.1007/s12185-022-03414-9. Epub 2022 Jul 12. Int J Hematol. 2022. PMID: 35821550 Free PMC article.
Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis.
Onda Y, Kanda J, Kaneko H, Shimura Y, Fuchida SI, Nakaya A, Itou T, Yamamura R, Tanaka H, Shibayama H, Shimazu Y, Uchiyama H, Yoshihara S, Adachi Y, Matsuda M, Hanamoto H, Uoshima N, Kosugi S, Ohta K, Yagi H, Kanakura Y, Matsumura I, Hino M, Nomura S, Shimazaki C, Takaori-Kondo A, Kuroda J; Kansai Myeloma Forum. Onda Y, et al. Among authors: kanakura y. Ther Adv Hematol. 2022 Jun 24;13:20406207221104584. doi: 10.1177/20406207221104584. eCollection 2022. Ther Adv Hematol. 2022. PMID: 35785245 Free PMC article.
Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria.
Nishimura JI, Ando K, Masuko M, Noji H, Ito Y, Mayer J, Griskevicius L, Bucher C, Müllershausen F, Gergely P, Rozenberg I, Schubart A, Chawla R, Rondeau JM, Roguska M, Splawski I, Keating MT, Johnson L, Danekula R, Bagger M, Watanabe Y, Haraldsson B, Kanakura Y. Nishimura JI, et al. Among authors: kanakura y. Haematologica. 2022 Jun 1;107(6):1483-1488. doi: 10.3324/haematol.2020.265868. Haematologica. 2022. PMID: 35263983 Free PMC article. No abstract available.
419 results